淳厚基金调研海尔生物，淳厚信睿C(008187)近一年回报达12.89%

Core Viewpoint - Haier Biomedical's overseas business is strategically positioned to mitigate the impact of U.S. tariffs, with a focus on localizing operations and enhancing product competitiveness in various international markets [2] Group 1: U.S. Market Impact - Haier Biomedical's revenue from the U.S. market accounted for less than 2% of total revenue in 2024, indicating limited exposure to U.S. tariffs [2] - The company has preemptively stocked up on orders before the tariff implementation, minimizing potential disruptions [2] - The firm emphasizes building internal capabilities to navigate complex international challenges through a "one country, one policy" approach [2] Group 2: Overseas Market Performance - In 2024, overseas revenue reached 715 million yuan, a year-on-year decline of 8.73%, but showed double-digit growth when excluding the impact of solar vaccine projects [2] - The company has seen a resurgence in order deliveries since Q3 2024, with Q4 showing positive growth, indicating recovery from previous disruptions [2] - The localization strategy has yielded results, with various product lines experiencing growth despite industry downturns, particularly in Europe and Asia-Pacific regions [2] Group 3: M&A Strategy and Performance - Haier Biomedical employs a "concentric circle" merger and acquisition strategy, targeting industry leaders with strong technological barriers and significant growth potential [2] - The integration of acquired businesses has shown significant results, with double-digit compound annual growth rates for the liquid nitrogen business and substantial revenue growth for other acquired units [2] Group 4: Financial Performance - In 2024, the company's gross margin was 47.99%, affected by changes in accounting policies, but would be 50.43% under consistent accounting standards [2] - The net profit for 2024 was 381 million yuan, influenced by non-operating factors such as investment income from equity disposals [2] - The decline in net profit was also attributed to the effects of ongoing M&A integrations and increased minority interests from subsidiary growth [2]